A series of 3-(pyridin-2-yl-ethynyl)benzamide negative allosteric modulators of the metabotropic glutamate receptor 5 (mGluR5 NAMs) have been prepared. Starting from HTS hit 1 (IC(50): 926 nM), potent mGluR5 NAMs showing excellent potencies (IC(50)s<50 nM) and good physicochemical profiles were prepared by monitoring LipE values. One compound 26 showed excellent mGluR5 binding (K(i): 21 nM) and antagonism (IC(50): 8 nM), an excellent rat PK profile (CL: 12 mL/min/kg, %F: 85) and showed oral activity in a mouse 4-Plate Behavioral model of anxiety (MED: 30 mpk) and a mouse Stress Induced Hyperthermia model of anxiety (MED 17.8 mpk).

We have developed a first generation of hybrid sparsomycin–linezolid compounds into a new family of orally bioavailable biaryloxazolidinones that have activity against both linezolid-susceptible and -resistant Gram-positive bacteria as well as the fastidious Gram-negative bacteria Haemophilus influenzae and Moraxella catarrahalis. The convergent synthesis of these new compounds is detailed.

Development of a large-scale enantioselective synthesis of a lead compound containing a 3-aryl-3-trifluoromethyl-2-aminopropanol core is described. A single isomer of 3,3-disubstituted acrylic acid derivative was prepared via Perkin condensation or Horner-Wadsworth-Emmons olefination, followed by hydrolysis. The acid was converted to a chiral acryloxazolidinone derivative. Hydrogenation of the latter on Pd/C in the presence of MgBr(2) proceeded via a chelation-controlled conformation to yield the desired isomer with high selectivity. Subsequent Evans azidation, hydrogenation, reductive cleavage of the chiral auxiliary, and sulfonylation afforded the target compound as a single isomer in high overall yield.

Pleuromutilin derivatives comprised of varied core structures have been synthesized. Many of the compounds described were found to have surprisingly good antibacterial activity in vitro.

From the X-ray crystal structures of linezolid and the non-selective antibiotic sparsomycin, we have derived a new family of hybrid oxazolidinones. From this initial compound set we have developed a new biaryloxazolidinone scaffold that shows both potent antimicrobial activity as well as selective inhibition of ribosomal translation. The synthesis of these compounds is outlined.

Ring-cleaved pleuromutilin derivatives comprised of a [5.3.1] bicyclic core structure have been synthesized and evaluated in vitro as antibacterial agents. Four of the compounds described were found to have MICs ≤ 4 μg/mL against marker strains of Streptococcus pneumoniae and Staphylococcus aureus.

Nocathiacin I (1) was converted to its deoxy indole analogue, nocathiacin II (2), another natural product, by a unique and facile chemical process. This process was applied to nocathiacin IV (4), generating the lactone analogue of glycothiohexide alpha (5), which was also prepared from nocathiacin II by a mild hydrolytic process. In contrast to glycothiohexide alpha (3), this lactone analogue (5) was found to exhibit in vivo antibacterial efficacy in an animal (mouse) infection model.

Forty-five novel cephalosporin derivatives with activity against methicillin-resistant Staphylococcus aureus (MRSA) are described. The compounds contain novel cinnamic acid moieties at C-7 that were synthesized using a key Heck reaction followed by nucleophilic aromatic substitution reactions. The most active compound (41) displayed an MIC(90) against MRSA of 1.0 microg/mL, and a PD(50) of 0.8 mg/kg. Compound 14 was found to be very safe in a mouse model of acute toxicity.

A C-8 keto pleuromutilin derivative has been synthesized from the biotransformation product 8-hydroxy mutilin. A key step in the process was the selective oxidation at C-8 of 8-hydroxy mutilin using tetrapropylammonium perruthenate. The presence of the C-8 keto group precipitated interesting intramolecular chemistry to afford a compound (10) with a novel pleuromutilin-derived ring system.

Twenty-seven novel cephalosporin derivatives with activity against methicillin-resistant Staphylococcus aureus (MRSA) are described. The compounds contain novel acid moieties at C-7 that were synthesized using nucleophilic aromatic substitution reactions and Stille couplings. The most interesting compound (6) displayed an MIC90 against MRSA of 3.7 μg/mL, and an average PD50 of 3.9 mg/kg.

An unprecedented cyclooctane to cyclononene ring expansion in the pleuromutilin skeleton, affording two main products, has been discovered. The process entails an intramolecular cyclization of an olefin onto an oxonium ion, followed by 1,2 migration of a carbon of the cyclooctane ring.

Biotransformation of mutilin and pleurommilin by microbial cultures was investigated to provide a source of 8-hydroxymutilin or 8-hydroxypleuromutilin. LC/MS analysis of culture broths showed that several strains gave M+16 products from mutilin and one culture gave an M+16 product from pleuromutilin, suggesting addition of oxygen. Biotransformation products were extracted from culture broths with ethyl acetate, dried, and purified by chromatography on silica gel. Streptomyces griseus strains SC 1754 and SC 13971 (ATCC 13273) converted mutilin to (8S)-, (7S)-, and (2S)-hydroxymutilin. Cunninghamella echinulata SC 16162 (NRRL 3655) gave (2S)-hydroxymutilin or (2R)-hydroxypleuromutilin from biotransformation of mutilin or pleuromutilin, respectively. The biotransformation of mutilin by S. griseus strain SC 1754 was scaled up in 15-, 60-, and 100-L fermentations to produce a total of 49 g of (8S)-hydroxymutilin (BMS-303786), 17 g of (7S)-hydroxymutilin (BMS-303789) and 13 g of (2S)-hydroxymutilin (BMS-303782) from 162 g of mutilin.